购物车
- 全部删除
- 您的购物车当前为空
Trimetazidine dihydrochloride (Vastarel F) 是细胞保护性抗缺血剂,也用作缺血性心脏病或心绞痛的血管扩张剂,具有抗氧化,抗炎,抗伤害和胃保护作用。它可通过抑制脂肪酸代谢提高心肌葡萄糖利用率。
Trimetazidine dihydrochloride (Vastarel F) 是细胞保护性抗缺血剂,也用作缺血性心脏病或心绞痛的血管扩张剂,具有抗氧化,抗炎,抗伤害和胃保护作用。它可通过抑制脂肪酸代谢提高心肌葡萄糖利用率。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 313 | 现货 | |
50 mg | ¥ 453 | 现货 | |
100 mg | ¥ 659 | 现货 | |
500 mg | ¥ 1,780 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 188 | 现货 |
产品描述 | Trimetazidine dihydrochloride (Vastarel F) can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina. |
靶点活性 | Long-chain 3-ketoacyl thiolase (mitochondrial):75 nM |
体外活性 | TMZ给药可减小WT C57BL/6J心脏的心肌梗塞面积。AMPK与ERK信号传导途径共同介导了TMZ对缺血性损伤的心脏保护作用。Trimetazidine转变新陈代谢从脂肪酸氧化向葡萄糖氧化,并在缺氧条件下改善心肌细胞的收缩功能[2]。 |
体内活性 | TMZ给药可减小WT C57BL/6J心脏的心肌梗塞面积。AMPK与ERK信号传导途径共同介导了TMZ对缺血性损伤的心脏保护作用。Trimetazidine转变新陈代谢从脂肪酸氧化向葡萄糖氧化,并在缺氧条件下改善心肌细胞的收缩功能[2]。 |
细胞实验 | The H9C2 cells are randomly assigned into three groups: Sham group, in which the cells are treated with 0μM TMZ for 48 h and then cultured under normal oxygenation conditions (5% CO2, and 95% air); H/R group, in which cells are treated with 0 μM TMZ for 48 h and then cultured under H/R conditions; and H/R+TMZ group, in which cells are treated with 10 μM TMZ for 48 h and then subjected to H/R treatment. (Only for Reference) |
别名 | Yoshimilon, Kyurinett, 盐酸曲美他嗪, Vastarel F |
分子量 | 339.258 |
分子式 | C14H24Cl2N2O3 |
CAS No. | 13171-25-0 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 65 mg/mL (191.59 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.